Ahmer Irfan, Katherine E McElroy, Rui Zheng-Pywell, Andrea Gillis, Sushanth Reddy, Clayton Yates, Herbert Chen, J Bart Rose
{"title":"NET guidelines for white patients may not fit Asian patients.","authors":"Ahmer Irfan, Katherine E McElroy, Rui Zheng-Pywell, Andrea Gillis, Sushanth Reddy, Clayton Yates, Herbert Chen, J Bart Rose","doi":"10.1016/j.amjsurg.2024.116116","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Pancreatic neuroendocrine tumors (pNETs) are slow growing, malignant tumors that show different survival outcomes by race. Current size-based guidelines were largely developed in White patients. Our aim was to investigate tumor size and incidence of lymph node metastasis (LNM) between White and Asian pNET patients to evaluate generalizability of established guidelines.</p><p><strong>Methods: </strong>Using the National Cancer Database (NCDB), we conducted a multi-institutional analysis of patients with low grade, resected, nonfunctional, sporadic, non-metastatic pNETs. Chi-squared tests were implemented to determine correlation between PTS and LMN incidence as well as race and LMN incidence. A logistic regression model was utilized to determine correlation between LMN, tumor size, and race. Overall survival was assessed using the Kaplan-Meier method.</p><p><strong>Results: </strong>A total of 4977 pNET patients (205 Asian and 4772 White) were included in our analysis. Asian patients presented with smaller tumors (3.0 cm vs 3.9 cm, p = 0.029) but when grouped by size, there was no difference in the distribution (p = 0.77). White patients demonstrated a higher incidence of lymph node metastasis at presentation compared to Asian patients (27 % vs 19 %, p = 0.013), a higher likelihood of an R0 resection (95.3 % vs. 89.3 %, p < 0.0001). Within both populations, tumor size (<2 cm, 2-3 cm, and ≥3 cm) positively correlated with incidence of LNM (11.5 %, 24.6 %, and 39.1 %). No difference of LNM was seen between racial cohorts at PTS <3 cm, however, Asian patients were less likely to exhibit LNM at PTS ≥3 cm (28.2 % and 39.5 %, p = 0.04). Overall survival was not significantly different between racial groups (p = 0.92).</p><p><strong>Conclusion: </strong>Size based surgical resection guidelines for pancreatic neuroendocrine tumors based on a predominantly White patient population may not be generalizable to the Asian population. Within this population, we found the risk of lymph node metastasis did not increase at similar rates with increasing primary tumor size.</p>","PeriodicalId":7771,"journal":{"name":"American journal of surgery","volume":"240 ","pages":"116116"},"PeriodicalIF":2.7000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11745910/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.amjsurg.2024.116116","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/1 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Pancreatic neuroendocrine tumors (pNETs) are slow growing, malignant tumors that show different survival outcomes by race. Current size-based guidelines were largely developed in White patients. Our aim was to investigate tumor size and incidence of lymph node metastasis (LNM) between White and Asian pNET patients to evaluate generalizability of established guidelines.
Methods: Using the National Cancer Database (NCDB), we conducted a multi-institutional analysis of patients with low grade, resected, nonfunctional, sporadic, non-metastatic pNETs. Chi-squared tests were implemented to determine correlation between PTS and LMN incidence as well as race and LMN incidence. A logistic regression model was utilized to determine correlation between LMN, tumor size, and race. Overall survival was assessed using the Kaplan-Meier method.
Results: A total of 4977 pNET patients (205 Asian and 4772 White) were included in our analysis. Asian patients presented with smaller tumors (3.0 cm vs 3.9 cm, p = 0.029) but when grouped by size, there was no difference in the distribution (p = 0.77). White patients demonstrated a higher incidence of lymph node metastasis at presentation compared to Asian patients (27 % vs 19 %, p = 0.013), a higher likelihood of an R0 resection (95.3 % vs. 89.3 %, p < 0.0001). Within both populations, tumor size (<2 cm, 2-3 cm, and ≥3 cm) positively correlated with incidence of LNM (11.5 %, 24.6 %, and 39.1 %). No difference of LNM was seen between racial cohorts at PTS <3 cm, however, Asian patients were less likely to exhibit LNM at PTS ≥3 cm (28.2 % and 39.5 %, p = 0.04). Overall survival was not significantly different between racial groups (p = 0.92).
Conclusion: Size based surgical resection guidelines for pancreatic neuroendocrine tumors based on a predominantly White patient population may not be generalizable to the Asian population. Within this population, we found the risk of lymph node metastasis did not increase at similar rates with increasing primary tumor size.
胰腺神经内分泌肿瘤(pNETs)是一种生长缓慢的恶性肿瘤,其生存结局因种族而异。目前基于尺寸的指南主要是针对白人患者制定的。我们的目的是研究白人和亚裔pNET患者的肿瘤大小和淋巴结转移(LNM)发生率,以评估既定指南的普遍性。方法:使用国家癌症数据库(NCDB),我们对低级别,切除,无功能,散发性,非转移性pNETs患者进行了多机构分析。采用卡方检验确定PTS与LMN发病率以及种族与LMN发病率之间的相关性。采用logistic回归模型确定LMN、肿瘤大小和种族之间的相关性。采用Kaplan-Meier法评估总生存率。结果:我们的分析共纳入4977例pNET患者(205例亚洲人,4772例白人)。亚洲患者肿瘤较小(3.0 cm vs 3.9 cm, p = 0.029),但按大小分组时,分布无差异(p = 0.77)。与亚洲患者相比,白人患者在发病时表现出更高的淋巴结转移发生率(27%对19%,p = 0.013), R0切除的可能性更高(95.3%对89.3%,p)结论:以白人患者为主的胰腺神经内分泌肿瘤手术切除指南可能无法推广到亚洲人群。在这一人群中,我们发现淋巴结转移的风险并没有随着原发肿瘤大小的增加而增加。
期刊介绍:
The American Journal of Surgery® is a peer-reviewed journal designed for the general surgeon who performs abdominal, cancer, vascular, head and neck, breast, colorectal, and other forms of surgery. AJS is the official journal of 7 major surgical societies* and publishes their official papers as well as independently submitted clinical studies, editorials, reviews, brief reports, correspondence and book reviews.